Original Article
Sympathetic Cardioneuropathy in Dysautonomias
N Engl J Med 1997; 336:696-702March 6, 1997
- Abstract
Background
The classification of dysautonomias has been confusing, and the pathophysiology obscure. We examined sympathetic innervation of the heart in patients with acquired, idiopathic dysautonomias using thoracic positron-emission tomography and assessments of the entry rate of the sympathetic neurotransmitter norepinephrine into the cardiac venous drainage (cardiac norepinephrine spillover). We related the laboratory findings to signs of sympathetic neurocirculatory failure (orthostatic hypotension and abnormal blood-pressure responses associated with the Valsalva maneuver), central neural degeneration, and responsiveness to treatment with levodopa–carbidopa (Sinemet).
Methods
Cardiac scans were obtained after intravenous administration of 6-[18F]fluorodopamine in 26 patients with dysautonomia. Fourteen had sympathetic neurocirculatory failure — three with no signs of central neurodegeneration (pure autonomic failure), two with parkinsonism responsive to treatment with levodopa–carbidopa, and nine with central neurodegeneration unresponsive to treatment with levodopa–carbidopa (the Shy–Drager syndrome). The rates of cardiac norepinephrine spillover were estimated on the basis of concentrations of intravenously infused [3H]norepinephrine during catheterization of the right side of the heart.
Results
Patients with pure autonomic failure or parkinsonism and sympathetic neurocirculatory failure had no myocardial 6-[18F]fluorodopamine–derived radioactivity or cardiac norepinephrine spillover, indicating loss of myocardial sympathetic-nerve terminals, whereas patients with the Shy–Drager syndrome had increased levels of 6-[18F]fluorodopamine–derived radioactivity, indicating intact sympathetic terminals and absent nerve traffic. Patients with dysautonomia who did not have sympathetic neurocirculatory failure had normal levels of 6-[18F]fluorodopamine–derived radioactivity in myocardium and normal rates of cardiac norepinephrine spillover.
Conclusions
The results of 6-[18F]fluorodopamine positron-emission tomography and neurochemical analyses support a new clinical pathophysiologic classification of dysautonomias, based on the occurrence of sympathetic neurocirculatory failure, signs of central neurodegeneration, and responsiveness to levodopa–carbidopa.
Media in This Article
Figure 2
Mean (±SE) Concentrations of 6-[18F]Fluorodopamine–Derived Radioactivity in Myocardium and of Arterial Plasma 6-[18F]Fluorodihydroxyphenylacetic Acid as a Function of Time after the Infusion of 6-[18F]Fluorodopamine in Patients with the Shy–Drager Syndrome, Patients with Multiple-System Atrophy without Sympathetic Neurocirculatory Failure, and Normal Subjects.Figure 1
Thoracic PET Scans after the Intravenous Injection of 5 mCi of [13N]Ammonia and 1 mCi of 6-[18F]Fluorodopamine in a Normal Subject, a Patient with Pure Autonomic Failure, a Patient with the Shy–Drager Syndrome, and a Patient with Parkinsonism and Sympathetic Neurocirculatory Failure.Article Activity
- Article
Dysautonomias, derangements of sympathetic or parasympathetic nervous system function, are seen fairly often in neurology and cardiology. Autonomic hypofunction or failure has received the most attention,1 and its causes include drugs and disease-associated polyneuropathy (e.g., diabetes and amyloidosis). Less commonly, autonomic failure occurs without an identifiable cause or in association with a disease in which the pathophysiologic basis for dysautonomia remains obscure.
A consensus statement by the American Autonomic Society and the American Academy of Neurology2 distinguished three forms of primary dysautonomia: pure autonomic failure, defined as a sporadic, idiopathic cause of persistent orthostatic hypotension and other manifestations of autonomic failure that occurs without other neurologic features; Parkinson's disease with autonomic failure; and multiple-system atrophy, a sporadic, progressive disorder of adults characterized by autonomic dysfunction, parkinsonism, and ataxia in any combination. According to the consensus statement, in a patient with multiple-system atrophy, the term “striatonigral degeneration” applies when parkinsonism dominates the clinical picture; the term “olivopontocerebellar atrophy” is used when cerebellar features predominate; and the term “Shy–Drager syndrome” is used when autonomic failure predominates. Patients with parkinsonism in the setting of multiple-system atrophy have a poor or brief response to levodopa therapy (in the United States, a combination of levodopa and carbidopa [Sinemet] is used).
Except for the subjective impression of responsiveness to levodopa–carbidopa, the classification does not distinguish Parkinson's disease with autonomic failure from the striatonigral-degeneration subtype of multiple-system atrophy. The classification also treats all types of autonomic failure identically, despite the fact that sympathetic failure produces orthostatic hypotension and parasympathetic failure produces constipation and urinary retention. Moreover, subtypes of multiple-system atrophy defined only on the basis of the relative predominance of clinical manifestations may or may not reflect pathophysiologically distinct entities.
Physiologic and neurochemical tests have also failed to separate forms of dysautonomia adequately. For instance, most patients with pure autonomic failure have low antecubital venous plasma levels of norepinephrine, the sympathetic neurotransmitter, but some do not3; and patients with multiple-system atrophy have normal norepinephrine levels, regardless of the subtype.4
Positron-emission tomographic (PET) scanning after systemic administration of 6-[18F]fluorodopamine can be used to visualize sympathetic innervation of tissue.5,6 One might expect the absence of 6-[18F]fluorodopamine–derived radioactivity in myocardium in a patient with dysautonomia and diffuse sympathetic denervation. Analyses of trends in myocardial radioactivity over time can provide information about sympathoneural function.7 For instance, blockade of ganglionic neurotransmission increases 6-[18F]fluorodopamine–derived radioactivity in myocardium6,8 and might be expected in a patient with dysautonomia and functionally intact sympathetic terminals but absent sympathetic-nerve traffic.
Assessments of the rate of entry of norepinephrine into the cardiac venous drainage (cardiac norepinephrine spillover) provide a neurochemical means to examine sympathoneural function.9 Patients with autonomic failure can have virtually absent cardiac norepinephrine spillover,10,11 a situation consistent with the loss of functional cardiac sympathoneural terminals.11
We examined whether 6-[18F]fluorodopamine PET scanning and measurements of cardiac norepinephrine spillover could be used to identify pathophysiologically distinct forms of dysautonomia.
Methods
The study protocol was approved by the Clinical Research Subpanel of the National Institute of Neurological Disorders and Stroke. Each patient provided written informed consent.
Patients
Twenty-six patients referred for dysautonomia underwent testing at the National Institutes of Health Clinical Center. Fourteen had sympathetic neurocirculatory failure, as defined below. Nine had multiple-system atrophy that was unresponsive to levodopa–carbidopa (the Shy–Drager syndrome), two had parkinsonism that was responsive to levodopa–carbidopa and had neurogenic orthostatic hypotension, and three had pure autonomic failure. The remaining 12 patients did not have sympathetic neurocirculatory failure: 4 had multiple-system atrophy with parasympathetic dysfunction (urinary incontinence, urinary retention, and constipation), 2 reflex sympathetic dystrophy, 2 neurocardiogenic syncope, 2 idiopathic orthostatic tachycardia syndrome, 1 adrenal failure, and 1 baroreflex failure.
Sympathetic neurocirculatory failure was diagnosed on the basis of persistent orthostatic hypotension and characteristic blood-pressure abnormalities during and after the performance of the Valsalva maneuver — a progressive fall in blood pressure during phase II (normally, mean arterial pressure increases from its nadir by the end of phase II) and the lack of an increase in systolic pressure above base line during phase IV.12 The Shy–Drager syndrome was diagnosed on the basis of sympathetic neurocirculatory failure and progressive central neural degeneration — parkinsonism resistant to levodopa–carbidopa, progressive cerebellar ataxia, or supranuclear or bulbar palsy. Pure autonomic failure was diagnosed on the basis of sympathetic neurocirculatory failure without signs of central neural degeneration. Multiple-system atrophy with parasympathetic autonomic failure was diagnosed by the presence of central neural degeneration and persistent impotence, constipation, urinary incontinence, urinary retention, or decreased sweating, without specific evidence of sympathetic neurocirculatory failure.
Pet Scanning
For PET scanning the patient was positioned in a Posicam body scanner (Positron, Houston) or a General Electric Advance scanner (General Electric, Milwaukee), with his or her thorax in the gantry. Myocardial perfusion was assessed by PET scanning of the thorax for 20 minutes after a 1-minute infusion of 5 mCi of [13N]ammonia. 6-[18F]Fluorodopamine (specific activity, 0.2 to 1.0 Ci per millimole; dose in most cases, 1.0 mCi)6 was dissolved in about 10 ml of normal saline and, beginning at least one hour after the administration of [13N]ammonia, was infused intravenously at a constant rate for three minutes, with continuous thoracic PET scanning for up to three hours afterward. A brachial arterial cannula was inserted percutaneously for blood-pressure monitoring and blood sampling. For purposes of analysis, the total scanning time was divided into intervals of 5 to 30 minutes, and the tomographic results for each interval were assessed. Data acquisition was independent of the phase of the electrocardiographic cycle.
Kinetics of Norepinephrine in Cardiac Tissue
Most patients also underwent catheterization of the right side of the heart for the estimation of norepinephrine spillover into coronary-sinus plasma. A tracer amount of [3H]norepinephrine (levo-[2,5,6]-[3H]norepinephrine, New England Nuclear, Boston) was infused intravenously, with coronary-sinus blood flow measured by thermodilution and arterial and coronary-sinus blood sampled after at least 20 minutes.10,13
Blood Samples and Assays
Plasma obtained from arterial blood before and after the administration of 6-[18F]fluorodopamine was assayed for this compound and its deaminated metabolite, 6-[18F]fluorodihydroxyphenylacetic acid.6,14 Arterial and coronary-sinus plasma obtained during catheterization of the right side of the heart was assayed for endogenous and [3H]-labeled norepinephrine and for 1-dihydroxyphenylalanine (levodopa, the precursor of the catecholamines), dihydroxyphenylglycol (a neuronal metabolite of norepinephrine), and dihydroxyphenylacetic acid (a deaminated metabolite of dopamine).13 Concentrations corrected for the rate of decay (in nanocuries per milliliter) were adjusted for the dose of radioactive drug (in millicuries) per kilogram of body weight.
Statistical Analysis
Cardiac images were analyzed as described previously.6 Circular regions of interest (in which the diameters were about half the width of the ventricular wall) were created with time-averaged (5 to 20 minutes for [13N]ammonia and 5 to 180 minutes for 6-[18F]fluorodopamine) images of single slices. Radioactivity concentrations in two regions of interest in the left ventricular free wall and two in the septum were averaged.
PET data in patients with dysautonomia were compared with those in 22 healthy, normal subjects (age range, 22 to 82 years) who were studied at the National Institutes of Health.6 The rates of cardiac norepinephrine spillover in the patients were compared with those in 32 healthy subjects (age range, 18 to 69 years) who were studied at the Baker Medical Research Institute, Prahran, Victoria, Australia, or at Sahlgrenska University Hospital, Goteborg, Sweden.9 The rates of cardiac norepinephrine spillover and the cardiac arteriovenous increments in plasma levels of catechols (the differences between the venous and arterial concentrations) were assessed by dependent-means t-tests. Analyses of variance for repeated measures were used to assess differences in trends of 6-[18F]fluorodopamine–derived radioactivity in myocardium or plasma levels of 6-[18F]fluorodihydroxyphenylacetic acid between patients with the Shy–Drager syndrome and normal subjects. A P value of less than 0.05 was considered to indicate statistical significance.
Results
In healthy subjects, thoracic [13N]ammonia and 6-[18F]fluorodopamine PET scans were very similar (Figure 1Figure 1
Thoracic PET Scans after the Intravenous Injection of 5 mCi of [13N]Ammonia and 1 mCi of 6-[18F]Fluorodopamine in a Normal Subject, a Patient with Pure Autonomic Failure, a Patient with the Shy–Drager Syndrome, and a Patient with Parkinsonism and Sympathetic Neurocirculatory Failure.).Among the three patients with pure autonomic failure, one had a low concentration of arterial plasma norepinephrine in the supine position (22 pg per milliliter [0.13 nmol per liter]), whereas the other two had normal concentrations (167 and 133 pg per milliliter [0.99 and 0.79 nmol per liter]). None of the three patients had detectable 6-[18F]fluorodopamine–derived radioactivity in myocardium (Figure 1), cardiac norepinephrine spillover, or cardiac arteriovenous increments in plasma levels of levodopa, dihydroxyphenylglycol, or dihydroxyphenylacetic acid (Table 1Table 1
Mean Coronary-Sinus Blood Flow and Concentrations of Norepinephrine and Other Catechols in Patients with Dysautonomias and Normal Subjects.).All nine patients with the Shy–Drager syndrome had clearly visible 6-[18F]fluorodopamine–derived radioactivity in the left ventricle (Figure 1), and the level of radioactivity was higher than that in patients with multiple-system atrophy without sympathetic neurocirculatory failure and normal subjects (Figure 2Figure 2
Mean (±SE) Concentrations of 6-[18F]Fluorodopamine–Derived Radioactivity in Myocardium and of Arterial Plasma 6-[18F]Fluorodihydroxyphenylacetic Acid as a Function of Time after the Infusion of 6-[18F]Fluorodopamine in Patients with the Shy–Drager Syndrome, Patients with Multiple-System Atrophy without Sympathetic Neurocirculatory Failure, and Normal Subjects.). Patients with the Shy–Drager syndrome had normal rates of cardiac norepinephrine spillover and had higher arterial plasma levels of 6-[18F]fluorodihydroxyphenylacetic acid (Figure 2) than the normal subjects.Patients with multiple-system atrophy without sympathetic neurocirculatory failure had normal levels of 6-[18F]fluorodopamine–derived radioactivity in myocardium, normal rates of cardiac norepinephrine spillover, and in most cases, normal arteriovenous increments in plasma levels of levodopa, dihydroxyphenylglycol, and dihydroxyphenylacetic acid.
Both patients with parkinsonism that was responsive to levodopa–carbidopa and sympathetic neurocirculatory failure had undetectable levels of 6-[18F]fluorodopamine–derived radioactivity in myocardium (Figure 1) and no detectable cardiac norepinephrine spillover or arteriovenous increments in plasma levels of levodopa, dihydroxyphenylglycol, or dihydroxyphenylacetic acid (Table 1).
Discussion
Our results show that there are different types of deranged cardiac sympathetic neuronal function (sympathetic cardioneuropathy), a finding that supports both the concept that there are pathophysiologically distinct dysautonomias and the move to modify the clinical diagnostic classification of autonomic failure in adults.15,16 The absence of 6-[18F]fluorodopamine–derived radioactivity in the myocardium of the three patients with pure autonomic failure probably reflected a loss of postganglionic sympathetic terminals in cardiac tissue. Decreased activity of a sympathoneuronal membrane transporter can also produce this result7; however, the same patients had strong neurochemical evidence of cardiac sympathetic denervation: virtually no cardiac spillover of norepinephrine11 and no cardiac production of levodopa,11 dihydroxyphenylglycol,13 or dihydroxyphenylacetic acid.17,18
In contrast, patients with the Shy–Drager syndrome (multiple-system atrophy with sympathetic neurocirculatory failure) clearly had 6-[18F]fluorodopamine–derived radioactivity in myocardium, normal rates of cardiac spillover of norepinephrine, and substantial cardiac production of levodopa, dihydroxyphenylglycol, and dihydroxyphenylacetic acid, confirming the presence of functionally intact cardiac sympathetic terminals. In fact, these patients had higher myocardial concentrations of 6-[18F]fluorodopamine–derived radioactivity than normal subjects or patients with multiple-system atrophy and no sympathetic neurocirculatory failure. The increased radioactivity did not result from increases in either coronary blood flow or plasma concentrations of 6-[18F]fluorodopamine. Since the rates of loss of 6-[18F]fluorodopamine–derived radioactivity depend partly on ongoing sympathoneural traffic,7 decreased or absent sympathetic outflow to the heart can explain the increased myocardial radioactivity in patients with the Shy–Drager syndrome.
Plasma levels of 6-[18F]fluorodihydroxyphenylacetic acid reflect the metabolism of 6-[18F]fluorodopamine in sympathetic nerves.6,8 The elevated 6-[18F]fluorodihydroxyphenylacetic acid levels in patients with the Shy–Drager syndrome therefore probably reflected generalized increases in neuronal concentrations of 6-[18F]fluorodopamine, as would be expected if 6-[18F]fluorodopamine built up in the axoplasm as a result of a generalized absence of sympathetic-nerve traffic.7
When patients with multiple-system atrophy were stratified according to the occurrence of sympathetic neurocirculatory failure (persistent orthostatic hypotension, a progressive decline in blood pressure during performance of the Valsalva maneuver, and the lack of a phase IV increase in systolic blood pressure above base line after the maneuver), the findings on 6-[18F]fluorodopamine PET scanning and the neurochemical results clearly distinguished the two groups. The patients with sympathetic neurocirculatory failure (the Shy–Drager syndrome) had increased 6-[18F]fluorodopamine–derived radioactivity, and the patients without sympathetic neurocirculatory failure did not. These results suggest that the Shy–Drager syndrome differs pathophysiologically from multiple-system atrophy without sympathetic neurocirculatory failure, in that only the former is associated with decreased or absent sympathetic-nerve traffic.
The Shy–Drager syndrome has been thought to involve a central neural derangement of baroreflex function,19 because the patients have normal plasma norepinephrine levels while supine4,20 but deficient norepinephrine responses while standing.20 This explanation predicts that while supine, the patients should have normal sympathetic outflows; however, pathological reports concerning these patients have noted central nervous system lesions, such as in the intermediolateral columns of the spinal cord,21-24 that would decrease or abolish sympathetic-nerve traffic. Attempts to quantify sympathetic-nerve traffic directly by microneurography in patients with the Shy–Drager syndrome have failed.25-27
Our results further highlight the apparent paradox of normal entry of norepinephrine into the bloodstream in the setting of apparently decreased or absent postganglionic sympathetic-nerve traffic in patients with the Shy–Drager syndrome. “Constitutive neurosecretion” — spontaneous release of norepinephrine independent of sympathetic-nerve traffic — may explain this phenomenon. Studies of subjects with trimethaphan-induced abolition of postganglionic sympathoneural traffic28 and studies of laboratory animals29-31 support the existence of constitutive neurosecretion. The mechanisms of constitutive neurosecretion, if it occurs, in patients with the Shy–Drager syndrome are unknown.
Distinguishing between the Shy–Drager syndrome and parkinsonism with autonomic failure has proved particularly challenging diagnostically, since both entities feature progressive central neural degeneration, neurogenic orthostatic hypotension, and a failure of plasma norepinephrine levels to increase when patients are standing. From the consensus statement on the definition of these disorders,2 clinical responsiveness to levodopa treatment constitutes the only factor differentiating nigrostriatal degeneration from Parkinson's disease with autonomic failure. In our study, two patients with parkinsonism and sympathetic neurocirculatory failure had no 6-[18F]fluorodopamine–derived radioactivity in myocardium, in contrast with the patients with the Shy–Drager syndrome, who had increased radioactivity. This difference provides a clear distinction between these entities and supports the separate classification of Parkinson's disease with autonomic failure.
The frequency of orthostatic hypotension among patients with Parkinson's disease remains unknown. Clinicians may ascribe orthostatic hypotension in this setting to treatment with levodopa–carbidopa. The present findings in a small subgroup of patients do not warrant generalization to the overall population of patients with Parkinson's disease; however, they do demonstrate that orthostatic hypotension in patients with parkinsonism can reflect sympathetic denervation.
We propose a pathophysiologic classification of dysautonomias (Figure 3Figure 3
Pathophysiologic Classification of Dysautonomias Based on Clinical Physiologic and Laboratory Findings Indicating Sympathetic Neurocirculatory Failure, the Occurrence of Signs of Central Neurodegeneration, and Clinical Responsiveness to Levodopa–Carbidopa.) in which sympathetic neurocirculatory failure results from peripheral sympathetic denervation or decreased or absent sympathoneural traffic, with or without signs of central neural degeneration, and in which both parkinsonism with sympathetic neurocirculatory failure and multiple-system atrophy without sympathetic neurocirculatory failure differ from the Shy–Drager syndrome. The PET scanning and neurochemical results and the clinical distinctions based on the occurrence of sympathetic neurocirculatory failure, signs of central neurodegeneration, and responsiveness to levodopa–carbidopa support this classification scheme, which differs in some respects from that in the consensus statement.2 Refined clinical laboratory means to identify pathophysiologic mechanisms of dysautonomias should allow the development of more effective means to diagnose the type of dysautonomia in individual patients, establish a prognosis, and predict responses to therapy.
Source Information
From the Clinical Neuroscience Branch, National Institute of Neurological Disorders and Stroke (D.S.G., C.H., G.E., I.J.K.), and the Cardiology Branch, National Heart, Lung, and Blood Institute (R.O.C.), National Institutes of Health, Bethesda, Md.
Address reprint requests to Dr. Goldstein at Bldg. 10, Rm. 6N252, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Dr., MSC-1424, Bethesda, MD 20892-1424.
- References
References
1
Low PA, ed. Clinical autonomic disorders: evaluation and management. Boston: Little, Brown, 1993.
2
Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy: the Consensus Committee of the American Autonomic Society and the American Academy of Neurology
Web of Science | Medline3
Meredith IT ,Eisenhofer G ,Lambert GW ,Jennings GL ,Thompson J ,Esler MD . Plasma norepinephrine responses to head-up tilt are misleading in autonomic failure. Hypertension 1992;19:628-633
Web of Science | Medline4
Goldstein DS ,Polinsky RJ ,Garty M , et al. Patterns of plasma levels of catechols in neurogenic orthostatic hypotension. Ann Neurol 1989;26:558-563
CrossRef | Web of Science | Medline5
Goldstein DS ,Chang PC ,Eisenhofer G , et al. Positron emission tomographic imaging of cardiac sympathetic innervation and function. Circulation 1990;81:1606-1621
CrossRef | Web of Science | Medline6
Goldstein DS ,Eisenhofer G ,Dunn BB , et al. Positron emission tomographic imaging of cardiac sympathetic innervation using 6-[18F]fluorodopamine: initial findings in humans. J Am Coll Cardiol 1993;22:1961-1971
CrossRef | Web of Science | Medline7
Goldstein DS, Holmes C, Stuhlmuller JE, Lenders JWM, Kopin IJ. 6-[18F]Fluorodopamine PET scanning in the assessment of cardiac sympathoneural function. Clin Auton Res (in press).
8
Goldstein DS ,Grossman E ,Tamrat M , et al. Positron emission imaging of cardiac sympathetic innervation and function using 18F-6-fluorodopamine: effects of chemical sympathectomy by 6-hydroxydopamine. J Hypertens 1991;9:417-423
CrossRef | Web of Science | Medline9
Eisenhofer G ,Friberg P ,Rundqvist B , et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996;93:1667-1676
Web of Science | Medline10
Goldstein DS ,Cannon RO III ,Quyyumi A , et al. Regional extraction of circulating norepinephrine, DOPA, and dihydroxyphenylglycol in humans. J Auton Nerv Syst 1991;34:17-35[Erratum, J Auton Nerv Syst 1991;36:85.]
CrossRef | Medline11
Meredith IT ,Esler MD ,Cox HS ,Lambert GW ,Jennings GL ,Eisenhofer G . Biochemical evidence of sympathetic denervation of the heart in pure autonomic failure. Clin Auton Res 1991;1:187-194
CrossRef | Medline12
Orthostatic hypotension. In: Johnson RH, Lambie DG, Spalding JMK. Neurocardiology: the interrelationships between dysfunction in the nervous and cardiovascular systems. Vol. 13 of Major problems in neurology. London: W.B. Saunders, 1984:113-58.
13
Eisenhofer G ,Esler MD ,Meredith IT , et al. Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine. Circulation 1992;85:1775-1785
Web of Science | Medline14
Holmes C ,Eisenhofer G ,Goldstein DS . Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1994;653:131-138
CrossRef | Web of Science | Medline15
Mathias CJ . The classification and nomenclature of autonomic disorders -- ending chaos, resolving conflict and hopefully achieving clarity. Clin Auton Res 1995;5:307-310
CrossRef | Web of Science | Medline16
Schatz IJ . Farewell to the “Shy-Drager syndrome.“ Ann Intern Med 1996;125:74-75
Web of Science | Medline17
Kvetnansky R ,Armando I ,Weise VK , et al. Plasma dopa responses during stress: dependence on sympathoneural activity and tyrosine hydroxylation. J Pharmacol Exp Ther 1992;261:899-909
Web of Science | Medline18
Goldstein DS . Clinical assessment of sympathetic responses to stress. Ann N Y Acad Sci 1995;771:570-593
CrossRef | Web of Science | Medline19
Bannister R. Multiple-system atrophy and pure autonomic failure. In: Low PA, ed. Clinical autonomic disorders: evaluation and management. Boston: Little, Brown, 1993:517-25.
20
Ziegler MG ,Lake CR ,Kopin IJ . The sympathetic-nervous-system defect in primary orthostatic hypotension. N Engl J Med 1977;296:293-297
Full Text | Web of Science | Medline21
Saito F ,Tsuchiya K ,Kotera M . An autopsied case of Parkinson's disease manifesting Shy-Drager syndrome. Rinsho Shinkeigaku 1992;32:1238-1244
Medline22
Oppenheimer DR . Lateral horn cells in progressive autonomic failure. J Neurol Sci 1980;46:393-404
CrossRef | Web of Science | Medline23
Johnson RH ,Lee G de J ,Oppenheimer DR ,Spalding JM . Autonomic failure with orthostatic hypotension due to intermediolateral column degeneration: a report of two cases with autopsies. Q J Med 1966;35:276-292
Web of Science | Medline24
Oppenheimer D. Neuropathology and neurochemistry of autonomic failure. A. Neuropathology of autonomic failure. In: Bannister R, ed. Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. 2nd ed. Oxford, England: Oxford University Press, 1988:451-63.
25
Goldstein DS ,McRae A ,Holmes C ,Dalakas MC . Autoimmune autonomic failure in a patient with myeloma-associated Shy-Drager syndrome. Clin Auton Res 1996;6:17-21
CrossRef | Web of Science | Medline26
Kachi T ,Iwase S ,Mano T ,Saito M ,Kunimoto M ,Sobue I . Effect of L-threo-3,4-dihydroxyphenylserine on muscle sympathetic nerve activities in Shy-Drager syndrome. Neurology 1988;38:1091-1094
Web of Science | Medline27
Wallin BG, Elam M. Microneurography and autonomic dysfunction. In: Low PA, ed. Clinical autonomic disorders: evaluation and management. Boston: Little, Brown, 1993:243-52.
28
Rea RF ,Eckberg DL ,Fritsch JM ,Goldstein DS . Relation of plasma norepinephrine and sympathetic traffic during hypotension in humans. Am J Physiol 1990;258:R982-R986
Web of Science | Medline29
Martin TF . The molecular machinery for fast and slow neurosecretion. Curr Opin Neurobiol 1994;4:626-632
CrossRef | Medline30
Golding DW ,Pow DV . `Neurosecretion' by synaptic terminals in the locust corpus cardiacum: is non-synaptic exocytosis part of the regulated or the constitutive pathway? Biol Cell 1991;73:157-162
CrossRef | Web of Science | Medline31
Rose CP ,Cousineau D ,Goresky CA ,De Champlain J . Constitutive nonexocytotic norepinephrine release in sympathetic curves of in situ canine heart. Am J Physiol 1994;266:H1386-H1394
Web of Science | Medline
- Citing Articles (82)
Citing Articles
1
Olli Eskola, Tove J. Grönroos, Alexandru Naum, Päivi Marjamäki, Sarita Forsback, Jörgen Bergman, Sami Länkimäki, Jan Kiss, Timo Savunen, Juhani Knuuti, Merja Haaparanta, Olof Solin. (2012) Novel electrophilic synthesis of 6-[18F]fluorodopamine and comprehensive biological evaluation. European Journal of Nuclear Medicine and Molecular Imaging
CrossRef2
S. Orimo, T. Uchihara, T. Kanazawa, Y. Itoh, K. Wakabayashi, A. Kakita, H. Takahashi. (2011) Unmyelinated axons are more vulnerable to degeneration than myelinated axons of the cardiac nerve in Parkinson's disease. Neuropathology and Applied Neurobiology 37:7, 791-802
CrossRef3
Valeria Iodice, David A. Low, Ekawat Vichayanrat, Christopher J. Mathias. (2011) Cardiovascular autonomic dysfunction in MSA and Parkinson's disease: Similarities and differences. Journal of the Neurological Sciences 310:1-2, 133-138
CrossRef4
David S. Goldstein, LaToya Sewell, Yehonatan Sharabi. (2011) Autonomic dysfunction in PD: A window to early detection?. Journal of the Neurological Sciences 310:1-2, 118-122
CrossRef5
Samay Jain, David S. Goldstein. (2011) Cardiovascular dysautonomia in Parkinson Disease: From pathophysiology to pathogenesis. Neurobiology of Disease
CrossRef6
Maria G. Cersosimo, Eduardo E. Benarroch. (2011) Autonomic involvement in Parkinson's disease: Pathology, pathophysiology, clinical features and possible peripheral biomarkers. Journal of the Neurological Sciences
CrossRef7
Akira Nakashima. (2011) Proteasomal degradation of tyrosine hydroxylase and neurodegeneration. Journal of Neurochemistryno-no
CrossRef8
J. William Langston. 2011. The Emerging Entity of Pre-Motor Parkinson's Disease. , 93-104.
CrossRef9
Ines Armando, Van Anthony M. Villar, Pedro A. Jose. 2011. Dopamine and Renal Function and Blood Pressure Regulation. .
CrossRef10
Cyndya Shibao, Luis Okamoto, Italo Biaggioni. (2011) Pharmacotherapy of autonomic failure. Pharmacology & Therapeutics
CrossRef11
Francesco Fornai, Riccardo Ruffoli, Filippo S. Giorgi, Antonio Paparelli. (2011) The role of locus coeruleus in the antiepileptic activity induced by vagus nerve stimulation. European Journal of Neuroscience 33:12, 2169-2178
CrossRef12
Samay Jain. (2011) Multi-organ autonomic dysfunction in Parkinson disease. Parkinsonism & Related Disorders 17:2, 77-83
CrossRef13
Stanley Fahn, Joseph Jankovic, Mark Hallett. 2011. Atypical parkinsonism, parkinsonism-plus syndromes, and secondary parkinsonian disorders. , 197-240.
CrossRef14
David S. Goldstein. (2010) Neurocardiology: Therapeutic Implications for Cardiovascular Disease. Cardiovascular Therapeuticsno-no
CrossRef15
Antti Saraste, Hossam Sherif, Markus Schwaiger. 2010. PET Innervation and Receptors. , 140-153.
CrossRef16
Tjalf Ziemssen, Heinz Reichmann. (2010) Cardiovascular autonomic dysfunction in Parkinson's disease. Journal of the Neurological Sciences 289:1-2, 74-80
CrossRef17
David J. Brooks. (2010) Examining Braak's hypothesis by imaging Parkinson's disease. Movement Disorders 25:S1, S83-S88
CrossRef18
David J. Brooks, Klaus Seppi, . (2009) Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Movement Disorders 24:7, 949-964
CrossRef19
Riccardo Ruffoli, Paola Soldani, Livia Pasquali, Stefano Ruggieri, Antonio Paparelli, Francesco Fornai. (2008) Methamphetamine Fails to Alter the Noradrenergic Integrity of the Heart. Annals of the New York Academy of Sciences 1139:1, 337-344
CrossRef20
Yehonatan Sharabi, Richard Imrich, Courtney Holmes, Sandra Pechnik, David S Goldstein. (2008) Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension. Movement Disorders 23:12, 1725-1732
CrossRef21
Hyung J Chun, Jagat Narula, Leonard Hofstra, Joseph C Wu. (2008) Intracellular and extracellular targets of molecular imaging in the myocardium. Nature Clinical Practice Cardiovascular Medicine 5, S33-S41
CrossRef22
David S. Goldstein, Courtney Holmes, Takuya Sato, Miya Bernson, Neptune Mizrahi, Richard Imrich, Gilberto Carmona, Yehonatan Sharabi, Alexander O. Vortmeyer. (2008) Central dopamine deficiency in pure autonomic failure. Clinical Autonomic Research 18:2, 58-65
CrossRef23
Klaus Kopka, Otmar Schober, Stefan Wagner. (2008) 18F-labelled cardiac PET tracers: selected probes for the molecular imaging of transporters, receptors and proteases. Basic Research in Cardiology 103:2, 131-143
CrossRef24
Satoshi Orimo. (2008) Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies. Rinsho Shinkeigaku 48:1, 11-24
CrossRef25
Satoshi Orimo, Takeshi Amino, Toshiki Uchihara, Fumiaki Mori, Akiyoshi Kakita, Koichi Wakabayashi, Hitoshi Takahashi. (2007) Decreased cardiac uptake of MIBG is a potential biomarker for the presence of Lewy bodies. Journal of Neurology 254:S4, IV21-IV28
CrossRef26
Riikka Lautamäki, Dnyanesh Tipre, Frank M. Bengel. (2007) Cardiac sympathetic neuronal imaging using PET. European Journal of Nuclear Medicine and Molecular Imaging 34:S1, 74-85
CrossRef27
Satoshi Orimo, Atsushi Takahashi, Toshiki Uchihara, Fumiaki Mori, Akiyoshi Kakita, Koichi Wakabayashi, Hitoshi Takahashi. (2007) Degeneration of Cardiac Sympathetic Nerve Begins in the Early Disease Process of Parkinson?s Disease. Brain Pathology 17:1, 24-30
CrossRef28
Satoshi Orimo, Takeshi Amino, Atsushi Takahashi, Tohru Kojo, Toshiki Uchihara, Fumiaki Mori, Koichi Wakabayashi, Hitoshi Takahashi. (2006) Cardiac sympathetic denervation in Lewy body disease. Parkinsonism & Related Disorders 12, S99-S105
CrossRef29
Sara Ripa, Cesa Scaglione, Luigi Cesare Rusconi. (2006) Transient left ventricular apical ballooning at the onset of multiple system atrophy. Journal of Cardiovascular Medicine 7:8, 631-636
CrossRef30
Felix Geser, Gregor K. Wenning. (2006) The diagnosis of multiple system atrophy. Journal of Neurology 253:S3, iii2-iii15
CrossRef31
Yehonatan Sharabi, Basil Eldadah, Sheng-Ting Li, Rhaguveer Dendi, Sandra Pechnik, Courtney Holmes, David S. Goldstein. (2006) Neuropharmacologic Distinction of Neurogenic Orthostatic Hypotension Syndromes. Clinical Neuropharmacology 29:3, 97-105
CrossRef32
Roy Freeman. (2006) Assessment of cardiovascular autonomic function. Clinical Neurophysiology 117:4, 716-730
CrossRef33
David S. Goldstein. (2006) Orthostatic hypotension as an early finding in Parkinson’s disease. Clinical Autonomic Research 16:1, 46-54
CrossRef34
Joel Handler. (2005) Symptomatic Orthostatic Hypotension/Supine Hypertension. The Journal of Clinical Hypertension 7:10, 612-616
CrossRef35
Graeme Eisenhofer. (2005) Sympathetic nerve function. Clinical Autonomic Research 15:4, 264-283
CrossRef36
Jeffrey P. Moak, Basil Eldadah, Courtney Holmes, Sandra Pechnik, David S. Goldstein. (2005) Partial cardiac sympathetic denervation after bilateral thoracic sympathectomy in humans. Heart Rhythm 2:6, 602-609
CrossRef37
J.M. Jiménez-Hoyuela García, V. Campos Arillo, A.C. Rebollo Aguirre, J.J. Gómez Doblas, A. Gutiérrez Hurtado. (2005) Alteración precoz de la función adrenérgica cardíaca en los parkinsonismos con cuerpos de Lewy. Revista Española de Medicina Nuclear 24:2, 93-100
CrossRef38
Masayuki Sugie, Jun Goto, Mitsuru Kawamura, Hidekazu Ota. (2005) Increased norepinephrine-associated adrenomedullary inclusions in Parkinson's disease. Pathology International 55:3, 130-136
CrossRef39
Paul M. Kemp. (2005) Imaging the dopaminergic system in suspected parkinsonism, drug induced movement disorders, and Lewy body dementia. Nuclear Medicine Communications 26:2, 87-96
CrossRef40
Jens Jordan. (2005) Effect of water drinking on sympathetic nervous activity and blood pressure. Current Hypertension Reports 7:1, 17-20
CrossRef41
David S. Goldstein, Courtney Holmes, Horacio Kaufmann, Roy Freeman. (2004) Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clinical Autonomic Research 14:6, 363-368
CrossRef42
Murray Esler. (2004) An explanation of the unexpected efficacy of L-DOPS in pure autonomic failure. Clinical Autonomic Research 14:6, 356-357
CrossRef43
DAVID S. GOLDSTEIN. (2004) Functional Neuroimaging of Sympathetic Innervation of the Heart. Annals of the New York Academy of Sciences 1018:1, 231-243
CrossRef44
I. El Honsali, H. Benjelloun, C.L. Coghlan, M. Benomar. (2004) Symptomatologie fonctionnelle cardiovasculaire : intérêt de l’étude du profil autonomique. Annales de Cardiologie et d'Angéiologie 53:3, 137-143
CrossRef45
Shinji Saiki, Genjiro Hirose, Koichiro Sakai, Satoshi Kataoka, Ariyuki Hori, Misuzu Saiki, Muichi Kaito, Kotaro Higashi, Suzuka Taki, Kazuo Kakeshita, Susumu Fujino, Miho Miaki. (2004) Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. Journal of the Neurological Sciences 220:1-2, 105-111
CrossRef46
Nicola Pavese, Ornella Rimoldi, Alexander Gerhard, David J. Brooks, Paola Piccini. (2004) Cardiovascular effects of methamphetamine in Parkinson's disease patients. Movement Disorders 19:3, 298-303
CrossRef47
Gregor K Wenning, Carlo Colosimo, Felix Geser, Werner Poewe. (2004) Multiple system atrophy. The Lancet Neurology 3:2, 93-103
CrossRef48
A. Korchounov, K. R. Kessler, H. I. Schipper. (2004) Differential effects of various treatment combinations on cardiovascular dysfunction in patients with Parkinson's disease. Acta Neurologica Scandinavica 109:1, 45-51
CrossRef49
Jun Ren, James E. Porter, Loren E. Wold, Nicholas S. Aberle, Dhanasekaran Muralikrishnan, James R. Haselton. (2004) Depressed contractile function and adrenergic responsiveness of cardiac myocytes in an experimental model of Parkinson disease, the MPTP-treated mouse. Neurobiology of Aging 25:1, 131-138
CrossRef50
David S Goldstein. (2003) Dysautonomia in Parkinson's disease: neurocardiological abnormalities. The Lancet Neurology 2:11, 669-676
CrossRef51
Andr?? Diedrich, Jens Jordan, Jens Tank, John R Shannon, Rosemarie Robertson, Friedrich C Luft, David Robertson, Italo Biaggioni. (2003) The sympathetic nervous system in hypertension. Journal of Hypertension 21:9, 1677-1686
CrossRef52
Louis H. Weimer, Olajide Williams. (2003) Syncope and orthostatic intolerance. Medical Clinics of North America 87:4, 835-865
CrossRef53
BLAIR P. GRUBB, DANIEL J. KOSINSKI, YOUSUF KANJWAL. (2003) Orthostatic Hypotension:. Pacing and Clinical Electrophysiology 26:4p1, 892-901
CrossRef54
M. Esler, G. Lambert, H. P. Brunner-La Rocca, G. Vaddadi, D. Kaye. (2003) Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice. Acta Physiologica Scandinavica 177:3, 275-284
CrossRef55
Italo Biaggioni. (2003) Sympathetic control of the circulation in hypertension: lessons from autonomic disorders. Current Opinion in Nephrology and Hypertension 12:2, 175-180
CrossRef56
Ç. AKINCIOğLU, M. ÜNLÜ, T. TUNÇ. (2003) Cardiac innervation and clinical correlates in idiopathic Parkinsonʼs disease. Nuclear Medicine Communications 24:3, 267-271
CrossRef57
Bj
rn Holmberg, Bo Johnels, Kaj Blennow, Lars Rosengren. (2003) Cerebrospinal fluid A?42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Movement Disorders 18:2, 186-190
CrossRef58
Samir M Parikh, André Diedrich, Italo Biaggioni, David Robertson. (2002) The nature of the autonomic dysfunction in multiple system atrophy. Journal of the Neurological Sciences 200:1-2, 1-10
CrossRef59
C Mathias. (2002) Neurodegeneration, parkinsonian syndromes and autonomic failure. Autonomic Neuroscience 96:1, 50-58
CrossRef60
E Benarroch. (2002) New findings on the neuropathology of multiple system atrophy. Autonomic Neuroscience 96:1, 59-62
CrossRef61
Murray Esler, Magdalena Rumantir, David Kaye, Garry Jennings, Jacqui Hastings, Flora Socratous, Gavin Lambert. (2001) Sympathetic Nerve Biology In Essential Hypertension. Clinical and Experimental Pharmacology and Physiology 28:12, 986-989
CrossRef62
Stefan Braune. (2001) The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clinical Autonomic Research 11:6, 351-355
CrossRef63
David M Raffel, Donald M Wieland. (2001) Assessment of cardiac sympathetic nerve integrity with positron emission tomography. Nuclear Medicine and Biology 28:5, 541-559
CrossRef64
Graeme Eisenhofer. (2001) The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacology & Therapeutics 91:1, 35-62
CrossRef65
LORI L. ALTSHULER, LEE S. COHEN, MARGARET L. MOLINE, DAVID A. KAHN, DANIEL CARPENTER, JOHN P. DOCHERTY, RUTH W. ROSS. (2001) Treatment of Depression in Women: A Summary of the Expert Consensus Guidelines. Journal of Psychiatric Practice 7:3, 185-208
CrossRef66
Olaf Oldenburg, Anna Mitchell, Jens Nürnberger, Susanne Koeppen, Raimund Erbel, Thomas Philipp, Andreas Kribben. (2001) Ambulatory norepinephrine treatment of severe autonomic orthostatic hypotension. Journal of the American College of Cardiology 37:1, 219-223
CrossRef67
M. Kallio, T. Haapaniemi, J. Turkka, K. Suominen, U. Tolonen, K. Sotaniemi, V.-P. Heikkilä, V. Myllylä. (2000) Heart rate variability in patients with untreated Parkinson’s disease. European Journal of Neurology 7:6, 667-672
CrossRef68
David S. Goldstein, Cees Tack. (2000) Noninvasive detection of sympathetic neurocirculatory failure. Clinical Autonomic Research 10:5, 285-291
CrossRef69
David S. Goldstein, Cees Tack, Sheng-Ting Li. (2000) Sympathetic innervation and function in reflex sympathetic dystrophy. Annals of Neurology 48:1, 49-59
CrossRef70
Sheng-Ting Li, Cees J Tack, Lameh Fananapazir, David S Goldstein. (2000) Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology 35:7, 1867-1873
CrossRef71
David J. Goldstein, Karen Sundell. (1999) A review of the safety of selective serotonin reuptake inhibitors during pregnancy. Human Psychopharmacology: Clinical and Experimental 14:5, 319-324
CrossRef72
Guido Grassi, Murray Esler. (1999) How to assess sympathetic activity in humans. Journal of Hypertension 17:6, 719-734
CrossRef73
Michael Plaschke, Peter Trenkwalder, Herbert Dahlheim, Christian Lechner, Claudia Trenkwalder. (1998) Twenty-four-hour blood pressure profile and blood pressure responses to head-up tilt tests in Parkinsonʼs disease and multiple system atrophy. Journal of Hypertension 16:10, 1433-1441
CrossRef74
Horacio Kaufmann. (1998) Multiple system atrophy. Current Opinion in Neurology 11:4, 351-355
CrossRef75
Michael Schäfers, Hartmut Lerch, Thomas Wichter, Christopher G Rhodes, Adriaan A Lammertsma, Martin Borggrefe, Flemming Hermansen, Otmar Schober, Günter Breithardt, Paolo G Camici. (1998) Cardiac sympathetic innervation in patients with idiopathic right ventricular outflow tract tachycardia. Journal of the American College of Cardiology 32:1, 181-186
CrossRef76
S. Braune, M. Reinhardt, J. Bathmann, T. Krause, M. Lehmann, C. H. Lucking. (1998) Impaired cardiac uptake of meta-[ 123 I]iodobenzylguanidine in Parkinson's disease with autonomic failure. Acta Neurologica Scandinavica 97:5, 307-314
CrossRef77
Clifford B. Saper. (1998) ?All fall down?: The mechanism of orthostatic hypotension in multiple systems atropy and Parkinson's disease. Annals of Neurology 43:2, 149-151
CrossRef78
D. Linden, R. R. Diehl, P. Berlit. (1997) Sympathetic cardiovascular dysfunction in long-standing idiopathic Parkinson's disease. Clinical Autonomic Research 7:6, 311-314
CrossRef79
(1997) Abstracts. Clinical Autonomic Research 7:4, 200-215
CrossRef80
(1997) Disorders of the Autonomic Nervous System. New England Journal of Medicine 337:4, 278-280
Full Text81
R JOENOBLE, E PRYSTOWSKY. (1997) Syncope—An algorithmic approach. ACC Current Journal Review 6:3, 91-100
CrossRef82
Mathias, Christopher J., . (1997) Autonomic Disorders and Their Recognition. New England Journal of Medicine 336:10, 721-724
Full Text
